10x Genomics Q1 2026 net loss narrows to $13.5M; launches Atera platform

10x Genomics, Inc.

2026-Q1 EPS reported -$0.10 revenue$150,843,000

Revenue $150.8M (-3% YoY); +9% excluding $16.8M one-time license/royalty in Q1 2025.
Gross margin 70% vs 68%; operating loss $17M vs $39.3M prior year.
Net loss $13.5M vs $34.4M; cash $539.8M (+$112.9M YoY).
Launched Atera spatial whole-transcriptome platform; shipping expected H2 2026.
FY 2026 revenue guidance maintained at $600M-$625M (0-4% growth ex-2025 one-time).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

10x Genomics, Inc. reported the first quarter ended March 31, 2026 results: revenue $150.8 million, net income Net loss was $13.5 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: $150.8 million
Net income: Net loss was $13.5 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Revenue was $150.8 million for the first quarter of 2026, a 3% decrease from the corresponding period of 2025.

View on SEC.gov

Browse all earnings releases →

10x Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-032073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.